CKD screening: urinary albumin or uDKK3 or both?
Clicks: 5
ID: 323831
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.2
/100
5 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #33 of 100 articles by views in nephrology dialysis transplantation
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Approximately 750 million people worldwide suffer from chronic kidney diseases (CKD)—a leading cause of cardiovascular morbidity and premature mortality—but early identification of progressive kidney function decline in patients at risk is still a challenge. CKD diagnosis relies on estimated glomerular filtration rate (eGFR) and albuminuria screening, primarily reflecting glomerular injury. Nevertheless, in a substantial proportion of affected subjects progressive CKD initially remains undetected, since kidney function deteriorates through ongoing tubulointerstitial injury without significant albuminuria, a condition known as ‘non-albuminuric’ CKD. Urinary Dickkopf-3 (uDKK3) has emerged as an innovative biomarker of progressive CKD, which is expressed by proximal tubular epithelial cells as a response to continuing injury. It is secreted into the urine, where it signals ongoing fibrogenic activity within the kidney. Clinical studies across a broad range of CKD etiologies—in adults and children alike—have shown that elevated uDKK3 significantly improved detection and prediction of progressive CKD after adjustment for established CKD risk markers including albuminuria. Moreover, in primarily non-albuminuric populations, e.g. those with type 2 diabetes and patients with heart or lung diseases, uDKK3 identifies high-risk individuals for future decline of kidney function. These findings support the hypothesis that CKD progression follows different pathways of mainly glomerular or tubulointerstitial injury. It is therefore plausible to use complementary biomarkers for CKD screening—albuminuria and uDKK3–each reflecting a distinct biological dimension of kidney injury. We discuss the limitations of albuminuria screening and propose a framework for integrating tubular markers like uDKK3 into future CKD screening strategies.
| Reference Key |
openalex_W7172486609
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Stefan Neuhaus, Danilo Fliser, Stefan Schunk |
| Journal | nephrology dialysis transplantation |
| Year | 2026 |
| DOI |
10.1093/ndt/gfag166
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.